A TWO-PART, PHASE 1A/B, OPEN-LABEL, MULTICENTER TRIAL EVALUATING PHARMACOKINETICS, SAFETY AND EFFICACY OF PF-07284890 (ARRY-461) IN PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS WITH AND WITHOUT BRAIN INVOLVEMENT
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
November 19, 2020
End Date
December 9, 2025
Administered By
Duke Cancer Institute
Awarded By
Pfizer, Inc.
Start Date
November 19, 2020
End Date
December 9, 2025